ESC Professional Premium Access

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Congress Presentation

About the speaker

Doctor Aya Shiraki

Saga University, Saga (Japan)
0 follower

5 more presentations in this session

Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.

Speaker: Mrs P. Nikolaou (Athens, GR)


Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents

Speaker: Doctor M. Sagris (Athens, GR)


Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.

Speaker: Doctor I. Ikonomidis (Athens, GR)


Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data

Speaker: Mr G. Wolff (Duesseldorf, DE)


Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Speaker: Doctor M. Malik (Copenhagen, DK) Doctor A. Falkentoft (Roskilde, DK)


Access the full session

Anti-diabetic pharmacotherapy in clinical practice

Speakers: Doctor A. Shiraki, Mrs P. Nikolaou, Doctor M. Sagris, Doctor I. Ikonomidis, Mr G. Wolff...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb